Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: A prospective patient cohort at a single institution

Annals of Surgical Oncology

Volumn 18, Issue 10, 2011, Pages 2937-2945

  Metellus, Philippe ^a,b,c   Nanni Metellus, Isabelle ^d   Delfino, Christine ^b,c   Colin, Carole ^b,c   Tchogandjian, Aurelie ^b,c   Coulibaly, Bema ^a,b,c   Fina, Frederic ^d   Loundou, Anderson ^b,d   Barrie, Marylin ^a   Chinot, Olivier ^a,b,c   Ouafik, L'Houcine ^b,c,d   Figarella Branger, Dominique ^a,b,c  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c University of the Mediterranean Aix Marseille II   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER SURGERY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; ANTIGENS, CD; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; COHORT STUDIES; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80052709582     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-1703-6     Document Type: Article

References (24)

1. F Berger E Gay L Pelletier P Tropel D Wion 2004 Development of gliomas: potential role of asymmetrical cell division of neural stem cells Lancet Oncol 5 511 514 15288241 10.1016/S1470-2045(04)01531-1 1:CAS:528:DC%2BD2cXmt1Kjsr0%3D (Pubitemid 39069402)
2. N Sanai A Alvarez-Buylla MS Berger 2005 Neural stem cells and the origin of gliomas N Engl J Med 353 811 822 16120861 10.1056/NEJMra043666 1:CAS:528:DC%2BD2MXovVOru7g%3D (Pubitemid 41215490)
3. D Beier J Wischhusen W Dietmaier P Hau M Proescholdt A Brawanski, et al. 2008 CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors Brain Pathol 18 370 377 18371181 10.1111/j.1750-3639. 2008.00130.x (Pubitemid 351782845)
4. AL Vescovi R Galli BA Reynolds 2006 Brain tumour stem cells Nat Rev Cancer 6 425 436 16723989 10.1038/nrc1889 1:CAS:528:DC%2BD28XkvVylt78%3D
5. SK Singh C Hawkins ID Clarke JA Squire J Bayani T Hide, et al. 2004 Identification of human brain tumour initiating cells Nature 432 396 401 15549107 10.1038/nature03128 1:CAS:528:DC%2BD2cXpvVCjtbY%3D (Pubitemid 39551674)
6. S Bao Q Wu Z Li S Sathornsumetee H Wang RE McLendon, et al. 2008 Targeting cancer stem cells through L1CAM suppresses glioma growth Cancer Res 68 6043 6048 18676824 10.1158/0008-5472.CAN-08-1079 1:CAS:528:DC%2BD1cXpt1Sqt7w%3D
7. AT Ogden AE Waziri RA Lochhead D Fusco K Lopez JA Ellis, et al. 2008 Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas Neurosurgery 62 505 514 18382330 10.1227/01.neu.0000316019.28421.95 discussion 514-5
8. A Tchoghandjian N Baeza C Colin M Cayre P Metellus C Beclin, et al. 2010 A2B5 cells from human glioblastoma have cancer stem cell properties Brain Pathol 20 211 221 19243384 10.1111/j.1750-3639.2009.00269.x
9. A Eramo L Ricci-Vitiani A Zeuner R Pallini F Lotti G Sette, et al. 2006 Chemotherapy resistance of glioblastoma stem cells Cell Death Differ 13 1238 1241 16456578 10.1038/sj.cdd.4401872 1:CAS:528:DC%2BD28Xls1Khtrs%3D (Pubitemid 43905604)
10. G Liu X Yuan Z Zeng P Tunici H Ng IR Abdulkadir, et al. 2006 Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma Mol Cancer 5 67 17140455 10.1186/1476-4598-5-67 (Pubitemid 44942887)
11. S Bao Q Wu RE McLendon Y Hao Q Shi AB Hjelmeland, et al. 2006 Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 756 760 17051156 10.1038/nature05236 1:CAS:528: DC%2BD28Xht1OntbzP (Pubitemid 44949604)
12. R Pallini L Ricci-Vitiani GL Banna M Signore D Lombardi M Todaro, et al. 2008 Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme Clin Cancer Res 14 8205 8212 19088037 10.1158/1078-0432.CCR-08-0644 1:CAS:528:DC%2BD1cXhsV2it7jN
13. F Zeppernick R Ahmadi B Campos C Dictus BM Helmke N Becker, et al. 2008 Stem cell marker CD133 affects clinical outcome in glioma patients Clin Cancer Res 14 123 129 18172261 10.1158/1078-0432.CCR-07-0932 1:CAS:528:DC%2BD1cXoslCg (Pubitemid 351377986)
14. DN Louis H Ohgaki OD Wiestler WK Cavenee PC Burger A Jouvet, et al. 2007 The 2007 WHO classification of tumours of the central nervous system Acta Neuropathol 114 97 109 17618441 10.1007/s00401-007-0243-4 (Pubitemid 47103521)
15. DR Macdonald TL Cascino SC Schold Jr JG Cairncross 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 2358840 1:STN:280:DyaK3c3ptlyitQ%3D%3D (Pubitemid 20195640)
16. P Metellus B Coulibaly I Nanni F Fina N Eudes R Giorgi, et al. 2009 Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort Cancer 115 4783 4794 19637364 10.1002/cncr.24546 1:CAS:528:DC%2BD1MXhtlGns7nK
17. SK Singh ID Clarke M Terasaki VE Bonn C Hawkins J Squire, et al. 2003 Identification of a cancer stem cell in human brain tumors Cancer Res 63 5821 5828 14522905 1:CAS:528:DC%2BD3sXnvVSjtbc%3D (Pubitemid 37187480)
18. DR Laks M Masterman-Smith K Visnyei B Angenieux NM Orozco I Foran, et al. 2009 Neurosphere formation is an independent predictor of clinical outcome in malignant glioma Stem Cells 27 980 987 19353526 10.1002/stem.15
19. N Thon K Damianoff J Hegermann S Grau B Krebs O Schnell, et al. 2010 Presence of pluripotent CD133(+) cells correlates with malignancy of gliomas Mol Cell Neurosci 43 51 59 18761091 10.1016/j.mcn.2008.07.022 1:CAS:528: DC%2BD1MXhs1Wgu7fM
20. M Zhang T Song L Yang R Chen L Wu Z Yang, et al. 2008 Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients J Exp Clin Cancer Res 27 85 19108713 10.1186/1756-9966-27-85 1:CAS:528:DC%2BD1cXhtlKitbjL
21. HS Phillips S Kharbanda R Chen WF Forrest RH Soriano TD Wu, et al. 2006 Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 9 157 173 16530701 10.1016/j.ccr.2006.02.019 1:CAS:528:DC%2BD28XivFWjtL4%3D (Pubitemid 43357943)
22. M Esteller J Garcia-Foncillas E Andion SN Goodman OF Hidalgo V Vanaclocha, et al. 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350 1354 11070098 10.1056/NEJM200011093431901 1:CAS:528:DC%2BD3cXosFOltLg%3D
23. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller, et al. 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 15758010 10.1056/NEJMoa043331 1:CAS:528:DC%2BD2MXit1Wktro%3D (Pubitemid 40349502)
24. D Beier S Rohrl DR Pillai S Schwarz LA Kunz-Schughart P Leukel, et al. 2008 Temozolomide preferentially depletes cancer stem cells in glioblastoma Cancer Res 68 5706 5715 18632623 10.1158/0008-5472.CAN-07-6878 1:CAS:528:DC%2BD1cXovVCns7w%3D